Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY: Prednisolone in Fibrotic Hypersensitivity Pneumonitis
NCT07210008Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial in fibrotic hypersensitivity pneumonitis (CHP) comparing Prednisolone with Placebo (2 arms). Primary endpoint: Absolute change in Forced Vital Capacity (% predicted) at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
fibrotic hypersensitivity pneumonitis (CHP)
Beyond the preview
Go deeper on NCT07210008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210008.